Aberrant B-Cell Activation in Systemic Lupus Erythematosus

作者：Na Kang, Xiaohang Liu, Xujie You, Wenbo Sun, Kabeer Haneef, Xiaolin Sun, Wanli Liu · 发表于：Kidney Diseases · 年份：2022 · DOI：10.1159/000527213 · 被引用次数：35 · 研究领域：Systemic Lupus Erythematosus Research、T-cell and B-cell Immunology、Monoclonal and Polyclonal Antibodies Research

Background: B lymphocytes (B cells) are essential in humoral response, and their activation is an important first step for the production of antibodies. However, aberrant B-cell activation is common in the development and progression of autoimmune diseases including systemic lupus erythematosus (SLE), which is characterized by the generation of superfluous autoantibodies. SLE exhibits clinical manifestation such as excessive inflammation and tissue damage. This review aims to summarize the recent emerging studies on aberrant B-cell activation and the associated concurrent therapeutic targets in SLE. Summary: Aberrant B-cell activation is closely associated with the pathogenesis of SLE. Among a variety of mechanisms, dysregulations of B-cell receptor (BCR), toll-like receptor (TLR), and B-cell activating factor receptor (BAFF-R) pathways are the common and dominating factors involved in aberrant B-cell activation. These aberrant signaling transductions play diverse and integrated roles in the development and the pathogenesis of SLE. Therapies targeting aberrant B-cell activation have shown promising efficacy in achieving the clinical alleviation of SLE, suggesting the discovery of new drug targets from these aberrant signaling pathways is imminent. Here, an integrated survey or review of published high-throughput sequencing database covering RNAs of B cells from SLE versus criteria-matched healthy cont...